Laman UtamaONCY • NASDAQ
add
Oncolytics Biotech Inc
Tutup sebelumnya
$0.60
Julat tahun
$0.47 - $1.53
Permodalan pasaran
47.93J USD
Bilangan Purata
299.51K
Nisbah P/E
-
Hasil dividen
-
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CAD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 8.44J | -4.66% |
Pendapatan bersih | -8.02J | -103.01% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.10 | 9.91% |
EBITDA | -8.43J | 4.56% |
Kadar cukai berkesan | -0.29% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CAD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 15.94J | -54.34% |
Jumlah aset | 20.19J | -48.00% |
Jumlah liabiliti | 14.20J | 26.18% |
Jumlah ekuiti | 5.98J | — |
Syer tertunggak | 86.42J | — |
Harga kepada buku | 8.55 | — |
Pulangan pada aset | -94.91% | — |
Pulangan pada modal | -245.72% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CAD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -8.02J | -103.01% |
Tunai daripada operasi | -7.85J | -28.12% |
Tunai daripada pelaburan | -6.00K | -100.00% |
Tunai daripada pembiayaan | 3.34J | 91.68% |
Perubahan bersih dalam tunai | -3.66J | 27.88% |
Aliran tunai bebas | -4.62J | 44.28% |
Perihal
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Diasaskan
1998
Ibu pejabat
Tapak web
Pekerja
28
